S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
Log in
CVE:RX

BioSyent Inc. (RX.V) Stock Forecast, Price & News

C$7.40
-0.25 (-3.27 %)
(As of 02/26/2021 03:25 PM ET)
Add
Compare
Today's Range
C$7.40
Now: C$7.40
C$7.65
50-Day Range
C$0.08
MA: C$7.43
C$7.92
52-Week Range
C$3.13
Now: C$7.40
C$8.49
Volume9,360 shs
Average Volume12,494 shs
Market CapitalizationC$94.76 million
P/E Ratio23.13
Dividend YieldN/A
BetaN/A
BioSyent Inc., a specialty pharmaceutical company, through its subsidiaries, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells and is indicated for the prevention of iron deficiency anemia; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository for the healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview, an adjunct to white-light cystoscopy for the detection and management of non-muscle invasive papillary bladder cancer. Its products also comprise Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis. In addition, it manufactures and markets Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains. BioSyent Inc. sells its products number of wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. is headquartered in Mississauga, Canada.

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-905-2060013
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$22.18 million
Cash FlowC$1.81 per share
Book ValueC$2.04 per share

Profitability

Miscellaneous

Market CapC$94.76 million
Next Earnings Date3/17/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

0.97 out of 5 stars

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
C$7.40
-0.25 (-3.27 %)
(As of 02/26/2021 03:25 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RX News and Ratings via Email

Sign-up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioSyent Inc. (RX.V) (CVE:RX) Frequently Asked Questions

Is BioSyent Inc. (RX.V) a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioSyent Inc. (RX.V) in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BioSyent Inc. (RX.V) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RX, but not buy additional shares or sell existing shares.
View analyst ratings for BioSyent Inc. (RX.V)
or view top-rated stocks.

What stocks does MarketBeat like better than BioSyent Inc. (RX.V)?

Wall Street analysts have given BioSyent Inc. (RX.V) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BioSyent Inc. (RX.V) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BioSyent Inc. (RX.V)'s next earnings date?

BioSyent Inc. (RX.V) is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for BioSyent Inc. (RX.V)
.

How were BioSyent Inc. (RX.V)'s earnings last quarter?

BioSyent Inc. (RX.V) (CVE:RX) issued its quarterly earnings data on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing analysts' consensus estimates of $0.08 by $0.02. The firm had revenue of $3.82 million for the quarter, compared to the consensus estimate of $4.80 million.
View BioSyent Inc. (RX.V)'s earnings history
.

How has BioSyent Inc. (RX.V)'s stock price been impacted by COVID-19 (Coronavirus)?

BioSyent Inc. (RX.V)'s stock was trading at C$4.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RX shares have increased by 70.1% and is now trading at C$7.40.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RX?

2 brokerages have issued 1 year price targets for BioSyent Inc. (RX.V)'s shares. Their forecasts range from C$7.00 to C$7.00. On average, they expect BioSyent Inc. (RX.V)'s stock price to reach C$7.00 in the next year. This suggests that the stock has a possible downside of 5.4%.
View analysts' price targets for BioSyent Inc. (RX.V)
or view top-rated stocks among Wall Street analysts.

Who are BioSyent Inc. (RX.V)'s key executives?

BioSyent Inc. (RX.V)'s management team includes the following people:
  • Mr. René C. Goehrum, Chairman, CEO & Pres
  • Mr. Robert J. March, VP of Fin. & CFO
  • Mr. Joost van der Mark, VP of Corp. Devel.
  • Ms. Neelu Atwal, Director of HR
  • Mr. Alfred D'Souza, Advisor

Who are some of BioSyent Inc. (RX.V)'s key competitors?

What other stocks do shareholders of BioSyent Inc. (RX.V) own?

What is BioSyent Inc. (RX.V)'s stock symbol?

BioSyent Inc. (RX.V) trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of BioSyent Inc. (RX.V)?

Shares of RX and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BioSyent Inc. (RX.V)'s stock price today?

One share of RX stock can currently be purchased for approximately C$7.40.

How much money does BioSyent Inc. (RX.V) make?

BioSyent Inc. (RX.V) has a market capitalization of C$94.76 million and generates C$22.18 million in revenue each year.

What is BioSyent Inc. (RX.V)'s official website?

The official website for BioSyent Inc. (RX.V) is www.biosyent.com.

Where are BioSyent Inc. (RX.V)'s headquarters?

BioSyent Inc. (RX.V) is headquartered at 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada.

How can I contact BioSyent Inc. (RX.V)?

BioSyent Inc. (RX.V)'s mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The company can be reached via phone at +1-905-2060013.


This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.